ARCA biopharma Appoints New Chief Medical Officer
Ticker: ORKA · Form: 8-K · Filed: Apr 23, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $200,000, $165,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, compensation
TL;DR
ARCA biopharma names Dr. Yaszemski as CMO, effective April 20th. New role comes with $350k salary + bonus/options.
AI Summary
ARCA biopharma, Inc. announced on April 23, 2024, that its Board of Directors appointed Dr. Michael J. Yaszemski as Chief Medical Officer, effective April 20, 2024. Dr. Yaszemski will receive an annual base salary of $350,000 and will be eligible for an annual bonus and stock options. The company also reported on the election of new directors and changes to its compensatory arrangements.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction and clinical development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can indicate strategic shifts or internal challenges within a company.
Key Numbers
- $350,000 — CMO Annual Base Salary (Compensation for Dr. Yaszemski)
Key Players & Entities
- ARCA biopharma, Inc. (company) — Registrant
- Dr. Michael J. Yaszemski (person) — Appointed Chief Medical Officer
- $350,000 (dollar_amount) — Annual base salary for CMO
- April 20, 2024 (date) — Effective date of appointment
- April 23, 2024 (date) — Date of report
FAQ
Who was appointed as the new Chief Medical Officer?
Dr. Michael J. Yaszemski was appointed as the new Chief Medical Officer.
When was the appointment of the new Chief Medical Officer effective?
The appointment was effective April 20, 2024.
What is the annual base salary for the new Chief Medical Officer?
The annual base salary for Dr. Michael J. Yaszemski is $350,000.
What other compensation is the new Chief Medical Officer eligible for?
Dr. Michael J. Yaszemski is eligible for an annual bonus and stock options.
What other items were reported in this 8-K filing?
The filing also reported on the election of directors and changes to compensatory arrangements of certain officers.
Filing Stats: 797 words · 3 min read · ~3 pages · Grade level 10 · Accepted 2024-04-23 16:20:10
Key Financial Figures
- $200,000 — ct to each such executive by 33.33%, to $200,000. The remaining portion of the retention
- $165,000 — er and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with th
Filing Documents
- abio-20240420.htm (8-K) — 43KB
- abio-ex10_1.htm (EX-10.1) — 21KB
- abio-ex10_2.htm (EX-10.2) — 21KB
- 0000950170-24-046918.txt ( ) — 203KB
- abio-20240420.xsd (EX-101.SCH) — 24KB
- abio-20240420_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Second Amendment to Retention Bonus Letter, dated April 22, 2024, by and between ARCA biopharma, Inc. and Thomas A. Keuer . 10.2 Second Amendment to Retention Bonus Letter, dated April 22, 2024, by and between ARCA biopharma, Inc. and C. Jeffrey Dekker . 104 Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: April 23, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer